Capricor Looks Ahead To Deramiocel Approval In DMD
With the FDA accepting its refiled BLA and setting an Aug. 22 PDUFA date, Capricor said its cell therapy could offer skeletal and cardiac benefits to Duchenne muscular dystrophy patients.
Scrip - March 12, 2026

Novo Holdings’ Assets Shrank As Novo Nordisk’s Value Sank
Novo Holdings’ annual report showed a -46.4% return on its Novo Nordisk shares in 2025 as the drugmaker struggled under the weight of competition. Its investment portfolio grew by 2.5%.
Scrip - March 12, 2026

BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9
The company presented updated data from the Phase III pivotal trial and plans to file for US FDA approval in the first half of the year.
Scrip - March 12, 2026

Executives On The Move: Seven Firms Get New CFOs
Recent moves in the industry include C-suite changes at Syntis Bio, Inimmune and Epigenic Therapeutics, plus Seres Therapeutics gets a new interim CEO from Merck & Co.  
Scrip - March 12, 2026

Almirall On The Lookout For More China Collaborations
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Scrip - March 12, 2026

Samsung Bioepis Sharpens Differentiation Strategy As Global ADC Market Matures
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
Scrip - March 12, 2026

FDA And Industry To Move Forward On Commitment Letter After Agreeing On Several Proposals
During the latest round of MDUFA negotiations, the FDA and medtech industry agreed to include language in the next commitment letter that would provide direction for the use of carryover funds from user fees. The parties also found agreement on several other topics.
Medtech Insight - March 13, 2026

Haleon Invests In China To Tap Into Growing Middle Class
A new oral health manufacturing site in Shanghai will help facilitate Haleon's push into China's tier 2 and 3 cities where the middle class population is rapidly expanding.
HBW Insight - March 13, 2026

US Consumer Health People Moves: AHPA Awards, Kimberly-Clark CIO, RäFoods, Eshbal
AHPA Awards Hero, Champion, Visionary and others at annual meeting; Kimberly-Clark’s information chief has major-merger experience; RäFoods’ marketing chief has history with CEO; and Eshbal adds VP for North America expansion.
HBW Insight - March 13, 2026

Cetaphil Antioxidant Duo Addresses Sensitive Skin, Niagen Bioscience Enters Global Skin Care
Galderma launches a day/night duo that delivers antioxidants in a formula designed for sensitive skin, while Niagen Biosciences expands from its largely dietary supplement portfolio into skin care with the debut of Niagen NanoCloud.
HBW Insight - March 13, 2026

Who’s Hired? Centrient Names Freeman To Replace Clements As CEO
Generics Bulletin brings you the most noteworthy recent appointments in the off-patent and value-added medicines space.
Generics Bulletin - March 12, 2026

FDA’s First PSG Batch Of 2026 Includes 98 Guidances
The US FDA released one of the highest numbers of product-specific guidances for generic development in a single batch.
Generics Bulletin - March 12, 2026

Hikma Debuts Nucynta ER Rival In US
Hikma has introduced the first US rival to Nucynta ER in the form of a tapentadol extended-release authorized generic. The launch comes after the firm reported annual sales that were up but profits that were down, with new CEO Said Darwazah promising to right the ship.
Generics Bulletin - March 12, 2026

Podcast: Onchilles Pharma’s Neutrophil-Derived Path To Pan-Cancer Therapy
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
In Vivo - March 12, 2026